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Abstract
Introduction Esmirtazapine is evaluated as a novel drug for
treatment of insomnia.
Purpose The present study was designed to assess residual
effects of single and repeated doses of esmirtazapine 1.5 and
4.5 mg on actual driving in 32 healthy volunteers in a double-
blind, placebo-controlled study. Treatment with single doses
of zopiclone 7.5 mg was included as active control.
Methods Treatments were administered in the evening. Driv-
ing performance was assessed in the morning, 11 h after drug
intake, in a standardized on-the-road highway driving test. The
primary study parameter was standard deviation of lateral
position (SDLP), a measure of “weaving”. All subjects were
subjected to CYP2D6 phenotyping in order to distinguish poor
metabolizers from extensive metabolizers of esmirtazapine.
Results Overall, esmirtazapine 1.5 mg did not produce any
clinically relevant change in SDLP after single and repeated
dosing. Driving impairment, i.e., a rise in SDLP, did occur
after a single-dose administration of esmirtazapine 4.5 mg but
was resolved after repeated doses. Acute driving impairment
was more pronounced after both doses of esmirtazapine in a
select group of poor metabolizers (N=7). A single-dose
zopiclone 7.5 mg also increased SDLP as expected.
Conclusion It is concluded that single and repeated doses
of 1.5 mg esmirtazapine are generally not associated with
residual impairment. Single-dose administration of 4.5 mg
esmirtazapine was associated with residual impairment that
generally resolved after repeated administration. Explorato-
ry analysis in a small group of poor CYP 2D6 metabolizers
suggested that these subjects are more sensitive to the
impairing effects of esmirtazapine on car driving.
Keywords Hypnotics.H1 antagonism.Driving.
Cognition.CYP2D6 phenotype
Introduction
Esmirtazapine maleate (Org 50081) is the maleate salt of
the S(+)-enantiomer of the racemic drug mirtazapine.
Racemic mirtazapine is marketed for the treatment of major
depressive disorder. Mirtazapine is a close analog of its
predecessor mianserin that also has been marketed for
major depressive disorder. Esmirtazapine and mirtazapine
bind to presynaptic α2 receptors as well as to postsynaptic
5HT2 and H1 receptors where they act as antagonists of the
endogeneous ligands (de Boer and Ruigt 1995b; Pinder and
van Delft 1983); however, compared with mirtazapine and
R-mirtazapine, esmirtazapine has higher affinity to 5-HT2
receptors and low affinity to the 5-HT3 receptors and to the
muscarinic receptors (de Boer et al. 1988; Kooyman et al.
1994). Esmirtazapine is under development for the treat-
ment of primary insomnia and hot flushes.
Antidepressants such as mirtazapine and mianserin are
well known for their sedative properties (Biswas et al.
ThistrialhasbeenregisteredatClinicalTrials.govasNCT00798395http://
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DOI 10.1007/s00213-010-2149-42003; Pinder and van Delft 1983). A range of studies have
demonstrated that these drugs produce subjective fatigue
and sleepiness and impair psychomotor function, cognition,
and actual driving performance after acute dosing and to a
lesser degree as well as after repeated dosing (Curran et al.
1986; Mattila et al. 1989; Ramaekers 2003; Ramaekers et
al. 1998; 1992; Ridout et al. 2003; Wingen et al. 2005;
2006). Several studies have demonstrated that mirtazapine
increases sleep efficiency, total sleep time, and slow wave
sleep in patients with major depressive disorder and in
healthy subjects (Anttila and Leinonen 2001; Radhakishun
et al. 2000; Ruigt et al. 1990; Schmid et al. 2006; Winokur
et al. 2000). Most of mirtazapine's abilities to produce
daytime sedation comes from H1 blockade which is known
to reduce arousal state in humans. Mirtazapine's action at
the 5-HT2A receptor may also contribute to its sedative
effect; however, antagonism at the 5-HT2A receptor is not
thought to be responsible for the residual sedative effects
seen following nighttime administration of mirtazapine. In
clinical practice, antidepressant drugs with H1 antagonistic
properties such as mirtazapine have been frequently used
for the treatment of insomnia comorbid with various
psychiatric disorders (Mayers and Baldwin 2005; Stahl
2008). Likewise, H1 antagonists such as antihistamines are
commonly sold over the counter as hypnotic drugs to treat
insomnia because of their sleep-inducing propensities
(Stahl 2008).
Mirtazapine and mianserin clearly have H1 antagonism as
their most potent pharmacological property. Yet both drugs
are dosed (i.e., 30 mg or more) far above the minimum dose
needed to obtain maximal binding to H1 receptors, in order
to achieve sufficient serotonergic and noradrenergic action
that is required for an antidepressant response. Mirtazapine
has a >100-fold higher potency for the H1 receptor than for
the 5HT3 and α2 receptors, and a tenfold higher potency for
5HT2 (De Boer and Ruigt 1995a;S t a h l2008). For
esmirtazapine, it is postulated that the action on sleep is
mediated via antagonism of both, the H1 and the 5-HT2A
receptors. The affinity of esmirtazapine to both receptors is
high. Considering the action of these drugs on the H1 and
5HT2 receptor alone, sleep-promoting doses of these drugs
can be far lower than the regular doses prescribed to treat
depression. Effective sleep-promoting doses of esmirtazapine
are expected to range between 1.5 and 4.5 mg. The
possibility of developing esmirtazapine as a drug for
treatment of insomnia however also raises the issue of
residual daytime drowsiness and driving impairment since
esmirtazapine elimination half-life is long (i.e., >20 h).
The effects of H1 antagonism by mianserin and
mirtazapine on actual driving performance has been
assessed by means of a standardized road-tracking task in
previous studies (Ramaekers 2003; Wingen et al. 2005).
Acute, daytime doses of mianserin 10 mg t.i.d. produced
elevations in standard deviation of lateral position (SDLP)
during on-the-road driving that were equivalent to the
effects of a blood alcohol concentration (BAC) >1.0 mg/ml
in the same driving test. After sub-chronic dosing, the
impairing effects of mianserin reduced in magnitude but
were still comparable to a blood alcohol concentration
between 0.5 and 0.8 mg/ml. The impairing effects of
mianserin (30–60 mg) on daytime SDLP however where
much less (i.e., comparable to a BAC <0.05 mg/ml) when
the drug was administered in the evening, even though
blood mianserin concentrations during driving after noctur-
nal and daytime doses were comparable (Ramaekers et al.
1998). Likewise, mirtazapine 15–30 mg also produced mild
residual driving impairment when administered as a
nocturnal dose. Single doses of mirtazapine 15 and 30 mg
produced elevations in SDLP that were comparable to
BACs of 0.5 and 0.8 mg/ml. However, mirtazapine no
longer produced any clinically relevant changes in driving
performance after 1 or 2 weeks of repeated dosing.
The effect of 5HT2A/2C antagonism on actual driving has
been previously assessed in a study by van Laar et al.
(2001). That study demonstrated that single and repeated
doses of ritanserin 5 mg b.i.d. increased nocturnal slow
wave sleep, but failed to affect driving performance and
sleepiness during daytime. This finding supports the present
notion that residual impairment from esmirtazapine, if any
at all, is more likely to arise from H1 blockade than from
5HT2 blockade.
The present study was designed to assess the effects of
low, nocturnal doses of esmirtazapine on the next-day
actual driving of healthy volunteers as assessed in a
standardized on-the-road driving test and in laboratory
performance tasks. Esmirtazapine is metabolized through
CYP2D6 and its clearance is twice as low in poor
metabolizers as compared to extensive metabolizers
(Brockmoller et al. 2007). In the design phase, it was
decided to select a representative population for this study,
without restrictions on CYP2D metabolizer status. This
allowed for an additional “post hoc” explorative analysis on
the effects of esmirtazapine on actual driving performance
for poor and extensive metabolizers as determined by
cytochrome P450 2D6 (CYP2D6) phenotyping.
Methods
Subjects
Thirty-two healthy subjects, 16 men and 16 women, mean
(SD) age=33 (9) years, were recruited by advertisement in
local newspapers. Subjects were screened by a telephone
interview and a health questionnaire, and all underwent a
medical examination (including a standard 12-lead electro-
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and drug and pregnancy screening). Selection was based on
the following inclusion criteria: possession of a valid
driving license for more than 3 years, driving experience
of >5,000 km per year on average, normal binocular visual
acuity corrected or uncorrected, willingness to use double-
barrier method of birth control, body mass index of 18 to
30 kg/m
2 and written informed consent.
Subjects who met one or more of the following criteria
were excluded from the study: history or present evidence
of a serious illness such as renal, hepatic, cardiovascular,
pulmonary, endocrine, neurologic or psychiatric, hemato-
logic, or gastrointestinal diseases; insomnia or other sleep
disorders; pregnancy (as determined at screening) or
breastfeeding; known hypersensitivity to medicinal drugs;
treatment with an investigational drug within 3 months
prior to screening; use of medicines (except oral contra-
ceptives and paracetamol); excessive smoking (more than
five cigarettes a day); night work or rotation shift work,
overconsumption of alcohol (more than 2 units per day) or
caffeine (more than five cups of regular coffee a day);
positive result of urine drug screening at the screening visit
for alcohol and/or drug of abuse.
The study was approved by the standing Medical Ethics
Committee of Maastricht University and was carried out in
compliance with the current revision of the Declaration of
Helsinki, International Conference on Harmonization
guideline for Good Clinical Practice.
Design and treatments
The study was conducted according to a randomized,
double-blind, placebo-controlled, four-way crossover de-
sign. Treatments were administered in separate 7-day series,
and treatment orders were balanced following a Williams
design and assigned by a predetermined randomization
schedule, stratified by gender. The following treatment
conditions were defined: nocturnal doses of 1.5 mg
esmirtazapine on day 1–7; nocturnal doses of 4.5 mg
esmirtazapine on day 1–7; nocturnal doses of placebo on
day 1–7; and nocturnal doses of placebo on day 1–6 and
zopiclone 7.5 mg on day 7. The zopiclone treatment was
included to serve as an active control and to demonstrate
(assay) sensitivity of the driving test to residual drug
effects. Zopiclone 7.5 mg has repeatedly been shown to
produce residual driving impairment the in standardized
highway driving test (Vermeeren 2004).
During days 1–7 of all treatment periods, trial medica-
tion was taken by the subjects at their homes. Subjects
recorded the time of administration in a diary. On days 2–6,
trial medication was taken in the evening, within 30 min
before going to bed. On day 1 and 7, trial medication was
administered under supervision of a research associate at a
fixed time of drug administration (i.e., 2130 hours). Sub-
jects went to bed within 1 h after drug intake. The washout
period between treatments was at least 7 days.
Driving tests and cognitive tests were administered at
days 2 and 8 of treatment, with the driving test starting on
average 11 h after drug intake (range, between 10 and 11.5 h)
and the cognitive and psychomotor tests starting approxi-
mately 13 h after drug intake. All subjects scored negative on
drug and alcohol screens at all times that were conducted on
test days prior to performance testing. A blood sample was
taken between the driving test and the cognitive psychomotor
performance tests. Subjects were instructed to refrain from
alcohol use 24 h prior to and throughout treatment periods. A
summary of treatment and performance assessments schedule
on day 2 and 8 is given in Fig. 1.
Performance tests
Driving and psychometric tests were trained during two
separate training sessions prior to the first treatment
condition in order to minimize learning effects.
Highway driving test
In the highway driving test (O'Hanlon 1984;O ' H a n l o ne ta l .
1982), the subjects operate a specially instrumented vehicle
for about 1 h over a 100 km primary highway circuit while
maintaining a constant speed (95 km/h) and a steady lateral
position between the delineated boundaries of the right
(slower) traffic lane. An electro-optical device mounted at
the rear back of the car continuously measures lateral
distance separating the vehicle and the left lane-line. This
signal is digitized at a rate of 4 Hz and stored on an onboard
computer disk file for later editing analysis. The off-line
editing routine involves removal of all data segments that
reveal signal loss, disturbance or occurrence of passing
maneuvers. The edited dataset is then used to calculate
means and variances for lateral position. SDLP is taken as
the primary outcome variable. SDLP is a measure of road
tracking error, in practical terms, a composite index of
allowed weaving, swerving, and overcorrecting. The high-
way driving test has been calibrated in a manner allowing
expression of any sedative drug effect in terms of the BAC
required to achieve the equivalent level of driving impair-
ment (Louwerens et al. 1987). The alcohol calibration curve
demonstrates that drinkers' mean SDLP rises exponentially
with BAC. Results from the alcohol calibration study can be
used for describing drugs' effects on SDLP in terms of
respective BAC equivalencies. The change in SDLP at a
BAC of 0.5 mg/ml has been used as a criterion level to
quantify drug effects. Any drug-induced changes in SDLP
that exceed this criterion value are defined as clinically
relevant impairing drug effect in the present study.
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The word learning task is a verbal memory test for the
assessment of immediate recall and delayed recall. Fifteen
monosyllabic nouns sounded for 2 s. At the end of the
sequence the subject is asked to recall as many words as
possible (recall-order unimportant). The number correct is
scored as the first trial score. This procedure is repeated
three times and the summed trial score is referred to as the
immediate recall score (number). After a delay of at least
20 min, the subject is again required to recall as many
words as possible (without new presentation of the nouns).
The number correct is referred to as the delayed recall score
(number). The word learning task was conducted during the
highway driving test.
The stop-signal task requires subjects to make quick key
responses to visually presented go signals and to inhibit any
response when a visual stop signal is suddenly presented. The
current testisadapted fromanearlier version ofFillmore etal.
(2002) and has been validated for showing stimulant and
sedative drug effects (Ramaekers et al. 2006; Ramaekers and
Kuypers 2006). The go signals were four 1.5-cm letters
(ABCD) presented one at a time in the center of a computer
screen. Subjects were required to respond to each letter as
quickly as possible by pressing one of two response buttons.
One button is pressed to indicate that “A” or “C” appeared
and the other to indicate “B” or “D”. Letters were displayed
for 500 ms and the computer screen was blank for 1.5-s
interstimulus interval before the next letter was displayed.
This provides a period of 2 s during which the subject can
respond to a letter. A single test consists of 176 trials in
which each of the four-letter stimuli is presented equally
often. A stop signal occurs in 48 trials during a test. The stop
signal consists of visual cue, i.e., “*”, that appears in one of
the four corners of the screen. Subjects are required to
withhold any response when a stop-signal is presented. The
task lasts about 10 min. Primary dependant variable is
reaction time in stop trials (millisecond). Secondary param-
eters are response time (millisecond) in go trials and number
of errors in go and stop trials (number).
The critical tracking task measures the subject's ability to
control a displayed error signal in a first-order compensa-
tory tracking task. Error is displayed as a horizontal
deviation of a cursor from the midpoint on a horizontal,
linear scale. Compensatory joystick movements null the
error by returning the cursor to the midpoint. The frequency
at which the subject loses the control is the critical
frequency or λc (radians per second). The test includes five
trials of which the lowest and the highest score are
removed; the average of the remaining scores is taken as
the final score.
The divided attention task measures the subject's ability
to divide attention between two tasks performed simulta-
neously. The primary task consist of tracking task as
described above but at a constant level of difficulty set at
50% of the subject's maximum capacity. Tracking error is
measured as the difference in millimeters between the
position of the cursor and the midpoint of the scale. In the
secondary task, the subject monitors a central display upon
which single digits are presented at 1-s intervals. The
occurrence of the digit “2” is a signal for the subject to
remove the foot from a pedal as rapidly as possible.
Interstimulus interval varies between 1 and 2 s. Mean
absolute tracking error (millimeters) and Average Reaction
Time (milliseconds) are the main performance measures.
CYP2D6 phenotyping
CYP2D6 characterization was performed prior to the first
intake of trial medication in period 1 of the four-period
drug intake
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Fig. 1 Summary of treatments and activities schedule on days 2 and 8 in every treatment condition. ZOP zopiclone 7.5 mg, PLA placebo
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dextromethorphan 30 mg together with 200 ml water before
bedtime. Subjects had to empty their bladder pre-dose.
Subsequently, subjects' morning urine was collected in
containers. The excretion ratio dextromethorphan/dextro-
rphan in urine determined the CYP2D6 metabolizer status
of each subject. Subjects with an excretion ratio ≥0.3 were
characterized as poor metabolizers, subject whose excretion
ratio <0.3 were characterized as extensive metabolizers. In
total, 7 (22%) subjects were classified as poor metabolizers
(4 males/3 females) and 25 (78%) subjects (12 males/13
females) as extensive metabolizers.
Pharmacokinetics
Blood samples (5 ml) for esmirtazapine determinations
were collected at the time points indicated in Fig. 1 and
processed to plasma. Plasma samples were stored and
frozen at −20°C and later analyzed by LC-MS-MS. The
lower limit of quantification is 0.02 ng/ml.
Statistics
Sample size was based on a power calculation for non-
inferiority between esmirtazapine 4.5 mg and placebo after
multiple-dose administration with respect to actual driving
performance as assessed by means of SDLP. Given a mean
population standard deviation of 4.0 cm, a mean difference
in SDLP of 0.5 cm between multiple dose esmirtazapine
4.5 mg and placebo, a test–retest ≥0.70 and a non-
inferiority margin of 2.5 cm, a sample size of 26 subjects
is sufficient to demonstrate non-inferiority with a power of
at least 90% and a two-sided α-level of 0.05. This sample
size is also sufficiently large (i.e., power of at least 90%) for
detecting a clinically relevant effect of 2.5-cm mean
difference in SDLP between single-dose zopiclone 7.5 mg
and placebo to demonstrate assay-sensitivity. Taking into
account the possibility of drop-outs the total sample size
was set at N=32 or 8 subjects per treatment crossover
sequence stratified by gender (i.e., four males and four
females).
Estimation of differences in SDLP between poor and
extensive CYP 2D6 metabolizers was not pre-specified as
an objective of this study, and hence, the study was not
powered for these subgroup analyses. Therefore, the results
of these subgroups have to be interpreted in the perspective
of the explorative character of these analyses.
Statistical analyses of the driving, cognition, and psycho-
motor function parameters was done using a mixed model
including fixed factors for treatment, period, treatment
sequence, gender, day, and treatment by day interaction.
Kenward–Roger approximation was used to estimate denom-
inator degrees of freedom. Subject was included as a random
factor and day as a repeated factor. No fixed structure was
assumedfortherepeatedmeasures (co)variance.Least-squares
estimates of contrasts to placebo and two-sided 95% CI were
obtained from this model for single-doses and multiple-doses
treatment separately. Efficacy analyses included all subjects
randomly assigned to treatment sequence, treated, for whom
results from at least one driving test during treatment was
available, and without any pre-defined protocol violations that
mightimpactefficacyconclusions.Adverseevents(AEs)were
coded using the MedDRA dictionary. AEs occurring during
the washout period were assigned to the treatment takenduring
the precedingtreatment period.AEs occurringbeforeintake of
zopiclone 7.5 mg in the placebo-zopiclone treatment period
were assigned to placebo. AE tabulations included the number
and percentage of subjects with at least one AE by MedDRA
preferred term. Safety analyses included all subjects that were
randomly assigned to treatment sequence and treated. For the
efficacy evaluation, all complete and incomplete data were
included in the statistical analyses (i.e. no imputation was
performed for missing data). Statistical analyses were per-
formed using SAS® version 9.1.3.
The aim of the present study was to compare next-day
driving performance, as expressed by the SDLP, of
esmirtazapine with placebo. The study was designed as a
non-inferiority trial, with evaluation of SDLP effects in
relation to a reference BAC concentration. For SDLP, non-
inferiority between treatments was concluded if the upper
limit of the two-sided 95% confidence interval (CI) of the
mean difference in SDLP between drug and placebo below
2.5 cm. The upper limit of the non-inferiority margin is
chosen such that it excludes with high certainty a drug
effect >BAC 0.5 mg/ml, which is considered clinically
relevant.
Results
A total of 32 subjects entered the study. Twenty-nine
subjects completed all four treatment periods whereas, three
subjects prematurely discontinued. Two subjects dropped
out during treatment with esmirtazapine 4.5 mg due to
adverse events. In one case, the subject complained of
asthenia, fatigue, and muscular weakness starting 25 min
after intake of the first dose and decided to stop study
participation. This subject was a poor CYP 2D6 metabo-
lizer and the adverse events were considered related to
study treatment. The other subject was discontinued after
being diagnosed with breast cancer. In the judgment of the
medical supervisor, this serious adverse event was not
likely to be related to study treatments. Another subject
dropped out between the third and fourth treatment period
because she could no longer adhere to study restrictions
relating to alcohol intake. Median compliance to trial
Psychopharmacology (2011) 215:321–332 325medication was 100% after single doses and multiple doses
of all treatments.
Highway driving, cognition, and psychomotor function
Overall, mean (SD) SDLP after single doses of esmirtaza-
pine 1.5 mg, esmirtazapine 4.5 mg, zopiclone 7.5 mg and
placebo were 19.6 (3.6), 20.3 (3.4), 20.6 (3.3), and 18.3
(2.9), respectively. Mean (SD) SDLP after repeated doses
of esmirtazapine 1.5 mg, esmirtazapine 4.5 mg and placebo
were 19.8 (3.6), 19.8 (3.8), and 19.5 (3.3), respectively.
Assay-sensitivity was clearly demonstrated as shown by
the inferiority of zopiclone 7.5 mg to placebo: i.e., the
lower limit of the 95% CI was above zero. Moreover, the
estimated mean difference in SDLP between zopiclone and
placebo was larger than the non-inferiority margin of
2.5 cm, with an upper limit of the 95% CI of 3.6 cm.
The primary endpoint, mean difference in SDLP after
multiple dose treatment of esmirtazapine 4.5 mg with
placebo, clearly showed non-inferiority, i.e., the upper limit
of the 95% CI of the estimated mean difference in SDLP of
multiple-dose esmirtazapine 4.5 mg vs. placebo was lower
than the non-inferiority margin of 2.5 cm. In agreement
with this finding, the estimated mean difference in SDLP
following single- and multiple-dose treatment of esmirta-
zapine 1.5 mg as compared to placebo, also showed non-
inferiority. However, following single doses of esmirtzapine
4.5 mg, non-inferiority to placebo could not be demon-
strated; the upper limit of the 95% CI of SDLP (3.2 cm)
exceeded the non-inferiority margin of 2.5 cm. The mean
(95% CI) differences from placebo in SDLP values for all
treatment conditions are shown in Fig. 2.
In total, 7 (22%) subjects were classified as poor
metabolizers and 25 (78%) subjects as extensive metabo-
lizers. The explorative analysis on poor metabolizers (N=7)
indicated inferiority compared to placebo following single-
dose administration of 1.5 and 4.5 mg esmirtazapine, as the
upper limits of the 95% CI of SDLP difference vs. placebo
exceeded the non-inferiority margin and the lower limits
were above zero. After multiple doses, non-inferiority was
demonstrated for the lower dose of esmirtazapine, but not
for the higher dose.
The analysis of the data subset from extensive metabo-
lizers (N=25) yielded results similar to those obtained from
the data of the entire study population. In extensive
metabolizers, non-inferiority was shown for the mean
difference vs. placebo in SDLP after a single dose of
esmirtazapine 1.5 mg and after multiple doses of esmirta-
zapine 1.5 and 4.5 mg. Non-inferiority vs. placebo was not
shown for SDLP after a single dose of esmirtazapine
4.5 mg. Mean (95% CI) SDLP in poor and extensive
metabolizers is shown in Fig. 3.
When comparing poor and extensive metabolizers, there
were no statistically significant differences between the two
metabolizer groups for any of the four treatment compar-
isons for interest (i.e., for the comparison of esmirtazapine
single dose of 1.5 mg to placebo (p=0.43), single dose of
4.5 mg to placebo (p=0.09), multiple dose of 1.5 mg to
placebo (p=0.26), and multiple dose of 4.5 mg to placebo
(p=0.29)). It should be noted that the study was not
powered to draw conclusions on non-inferiority within or
between subgroups.
Laboratory test demonstrated that the effects of zopi-
clone on cognition and psychomotor function were not
shown to be statistically different from placebo. In general,
the cognitive tests results for mirtazapine did not show clear
dose–response relationship or major differences between
the results following single-dose and multiple-doses ad-
ministration. Moreover, esmirtazapine did not show statis-
tical differences from placebo for most laboratory
measures, except for tracking error in the divided-attention
task. The performance on this task was statistically
significantly worse than placebo after single and multiple
doses of 1.5 mg and single doses of 4.5 mg esmirtazapine,
but not after multiple dose of 4.5 mg esmirtazapine.
Following esmirtazapine 1.5 mg single doses only, delayed
recall in the word learning task and response time in the
divided attention task also showed a statistically significant
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mance on cognitive and psychomotor measures is given in
Table 1.
Pharmacokinetics
A summary of mean (SD) and median esmirtazapine
concentrations is given in Table 2. In general, mean
and median esmirtazapine concentrations in poor metabo-
lizers were about twice as high as those of extensive
metabolizers.
Adverse events
Treatment of esmirtazapine for 7 days was generally safe
and well tolerated. Overall, somnolence and fatigue were
the most frequently reported adverse events. Somnolence
was mainly experienced by subjects treated with esmirta-
zapine 1.5 or 4.5 mg. A summary of adverse events
reported with incidence of at least 5% in any treatment
during all treatments and during the first 24 h after first
treatment dose is given in Table 3 and 4, respectively.
After single-dose administration, somnolence and fatigue
were also the most frequently reported adverse events. Note
that adverse events summarized under placebo were
reported on two single-dose days (i.e., combining the first
day of placebo in the zopiclone group and first day of
placebo in the placebo group). Furthermore, while the
single-dose safety evaluation of placebo and esmirtazapine
refer to the first day of treatment, the single-dose zopiclone
results refer to the seventh day of treatment., where subjects
are less likely to report AEs (including drug-related AE) if
these AE were already reported earlier during this treatment
period while on placebo. As can be seen in Table 4, the
overall frequency of adverse events as well as the
frequencies of reported somnolence and fatigue while on
zopiclone is lower than that reported while on placebo.
Discussion
Overall, non-inferiority vs. placebo was demonstrated for
multiple doses of 1.5 mg and multiple doses of 4.5 mg
esmirtazapine as compared to placebo. The results for these
esmirtazapine doses indicated that the overall effects of
esmirtazapine on car driving were mild and of no clinical
relevance after 1 week of dosing. However, following a
single dose of 4.5 mg esmirtazapine, non-inferiority could
not be demonstrated as compared to placebo. While the
mean SDLP difference vs. placebo was somewhat lower
than the effect observed with 0.05 BAC, the upper limit of
the 95% CI exceeded the non-inferiority margin. Thus, a
single dose of 4.5 mg esmirtazapine produced a statistically
and clinically significant driving impairment. After repeated
administration for 1 week, both doses of esmirtazapine did
not produce any residual impairment as is evident by the
finding that the 95% CI of mean difference in SDLP vs.
placebo always contained zero and its upper limit was well
below the non-inferiority margin. The finding of driving
impairment after single dose of 4.5 mg but not after single
doses of 1.5 mg esmirtazapine suggests that the acute effect
of esmirtazapine on driving impairment is dose dependent.
This effect rapidly resolves after repeated administration.
Previous studies (O'Hanlon and Ramaekers 1995;
Ramaekers 2003) on the effects of H1 antagonists on actual
driving performance have shown more pronounced effects
on SDLP than those observed after esmirtazapine in the
present study, however, the overall pattern was similar.
Antidepressants with strong H1 antagonistic activity such as
amitriptyline, imipramine, and doxepin all produced signif-
icant driving impairment after single doses administered
during the day. Difference in SDLP from placebo after
single doses of these sedating antidepressants were compa-
rable to those seen in drivers conducting the same test with
a blood alcohol concentration (BAC) of 0.8 mg/ml or
higher. The impairing effects of sedating antidepressants
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Fig. 3 Mean (95% CI) SDLP
difference from placebo after
single doses of esmirtazapine
(ESM) and after multiple doses
of ESM in poor (N=7) and
extensive metabolizers (N=25).
Single asterisk, non-inferiority
not shown, upper bound of the
95% CI is above the non-
inferiority margin of 2.5 cm
Psychopharmacology (2011) 215:321–332 327Table 1 Mean (SD) difference from placebo and95% CI for cognitive and psychomotor measures in all treatments after single (s) and multiple (m) doses
Parameter Drug/dose N Mean (SD) Difference
a 95% CI
a Significance
Word learning task
Immediate recall score (number) PLA (s) 31 26.3 (4.8)
ESM 1.5 (s) 29 24.4 (5.3) −1.7 [−3.8, 0.4]
ESM 4.5 (s) 29 26.6 (5.8) 0.4 [−1.2, 2.1]
ZOP (s) 29 26.0 (5.1) −0.1 [−2.0, 1.8]
PLA (m) 28 27.0 (5.7)
ESM 1.5 (m) 30 26.7 (6.5) 0.2 [−2.3, 2.6]
ESM 4.5 (m) 30 26.8 (5.9) −0.2 [−2.7, 2.3]
Delayed recall score (number) PLA (s) 31 9.3 (2.9)
ESM 1.5 (s) 29 7.8 (3.3) −1.4 [−2.5, −0.3]
b
ESM 4.5 (s) 29 8.6 (3.6) −0.7 [−1.6, 0.2]
ZOP (s) 28 8.7 (3.0) −0.6 [−1.5, 0.3]
PLA (m) 28 8.9 (3.3)
ESM 1.5 (m) 30 9.4 (3.5) 0.7 [−0.4, 1.8]
ESM 4.5 (m) 29 9.3 (3.1) 0.6 [−0.4, 1.6]
Divided attention task
Tracking error (mm) PLA (s) 31 19.9 (3.8)
ESM 1.5 (s) 29 21.3 (4.2) 1.4 [0.6, 2.3]
b
ESM 4.5 (s) 31 21.8 (4.3) 2.0 [0.9, 3.1]
b
ZOP (s) 29 20.1 (4.6) 0.2 [−0.9, 1.3]
PLA (m) 30 20.1 (4.5)
ESM 1.5 (m) 30 21.4 (4.1) 1.2 [0.1, 2.2]
b
ESM 4.5 (m) 30 21.1 (4.6) 0.9 [−0.1, 2.0]
Response time (ms) PLA (s) 31 1770 (246)
ESM 1.5 (s) 29 1899 (261) 139 [33, 246]
b
ESM 4.5 (s) 31 1859 (247) 95 [−3, 192]
ZOP (s) 29 1833 (205) 62 [−33, 157]
PLA (m) 30 1783 (228)
ESM 1.5 (m) 30 1812 (202) 27 [−50, 105]
ESM 4.5 (m) 30 1811 (211) 30 [−49, 109]
Critical tracking task
Critical frequency (rad/s) PLA (s) 31 3.43 (0.62)
ESM 1.5 (s) 30 3.36 (0.61) −0.10 [−0.22, 0.02]
ESM 4.5 (s) 32 3.29 (0.68) −0.15 [−0.33, 0.03]
ZOP (s) 30 3.38 (0.79) −0.05 [−0.22, 0.12]
PLA (m) 30 3.41 (0.72)
ESM 1.5 (m) 30 3.44 (0.62) 0.02 [−0.12, 0.16]
ESM 4.5 (m) 30 3.34 (0.70) −0.07 [−0.22, 0.08]
Stop-signal task
Stop reaction time (ms) PLA (s) 31 288 (48)
ESM 1.5 (s) 30 292 (46) 4 [−15, 23]
ESM 4.5 (s) 32 297 (51) 8 [−13, 30]
ZOP (s) 30 292 (49) 4 [−15, 23]
PLA (m) 30 285 (45)
ESM 1.5 (m) 30 297 (57) 13 [−11, 36]
ESM 4.5 (m) 30 288 (49) 3 [−18, 24]
aLeast square mean differences and 95% CIs obtained from mixed model analyses
bStatistically significantly different at 5% level
328 Psychopharmacology (2011) 215:321–332such as mirtazapine on next-day driving performance
however were markedly lower when given in the evening.
The impairing effects of antidepressants on driving were
mostly present after single doses but disappeared after
1 week of repeated dosing due to tolerance (Ramaekers
2003). Likewise, single doses of antihistamines have been
demonstrated to significantly increase SDLP in a dose-
related manner (O'Hanlon and Ramaekers 1995). However,
the impairing effects of antihistamines on actual driving
also resolved after 4–7 days after repeated dosing. In the
present study, a single dose of esmirtazapine 4.5 mg also
produced significant driving impairment, but the impairing
effects rapidly resolved after 1 week of repeated dosing.
The implications would be twofold. First, next-day driving
need not be a priori contraindicated for esmirtazapine
1.5 mg as overall it did not produce relevant driving
impairment after single and repeated doses. Second, next-
day driving is not advised for patients taking a higher dose
of esmirtazapine (i.e., 4.5 mg), but only during treatment
initiation or initially after dose increase.
However, while the overall effect of esmirtazapine on
driving performance is limited and transient, some subjects
may be more susceptible to drug effects on driving
impairment. In the case of esmirtazapine, which is a
substrate for CYP2D6, patients who are poor metabolizers
of CYP2D6 may experience greater impairment. In general,
CYP2D6 has high relevance in drug metabolism. CYP2D6
is involved in the metabolism of 20–25% of clinically used
drugs and exhibits a clinically relevant gene polymorphism
that modifies the pharmacokinetics in patients that are
either poor or extensive metabolizers (Ingelman-Sundberg
et al. 2007; Tomalik-Scharte et al. 2008). About 5–10% of
the Caucasian populations are poor metabolizers of
CYP2D6 substrates which may cause elevated substrate
concentrations in blood of these individuals. In the present
study, seven subjects (22%) were phenotyped as poor
metabolizers. Especially for 4.5 mg esmirtazapine, mean
and median plasma concentrations of esmirtazapine were
about twice as high as the levels observed in extensive
metabolizers. Poor metabolizers also appeared to be more
Table 3 Summary of adverse events with incidence of at least 5% in any treatment group
Adverse events Placebo Esmirtazapine 1.5 mg Esmirtazapine 4.5 mg Zopiclone 7.5 mg
(N=31) (N=30) (N=32) (N=30)
n (%) n (%) n (%) n (%)
Fatigue 11(35.5) 12(40.0) 9(28.1) 3(10.0)
Somnolence 1(3.2) 9(30.0) 10(31.3) 1(3.3)
Headache 2(6.5) 4(13.3) 1(3.1) 2(6.7)
Poor quality sleep 6(19.4) 3(10.0) 1(3.1) 1(3.3)
Dysgeusia 4(12.9) 2(6.7) 1(3.1) 1(3.3)
Nasopharyngitis 1(3.2) 2(6.7) 1(3.1) 0(0.0)
Dizziness 1(3.2) 2(6.7) 2(6.3) 1(3.3)
Disturbance in attention 1(3.2) 2(6.7) 1(3.1) 0(0.0)
Oral herpes 0(0.0) 2(6.7) 0(0.0) 0(0.0)
Oropharyngeal pain 0(0.0) 2(6.7) 0(0.0) 0(0.0)
Dry mouth 1(3.2) 1(3.3) 2(6.3) 0(0.0)
Vomiting 2(6.5) 0(0.0) 1(3.1) 1(3.3)
Irritability 2(6.5) 0(0.0) 0(0.0) 0(0.0)
Table 2 Mean (SD) and median esmirtazapine plasma concentrations (nanograms/millilter) in poor and extensive metabolizers
Extensive metabolizers Poor metabolizers Overall
(N=25) (N=7) (N=32)
Esmirtazapine Day 2 Day 8 Day 2 Day 8 Day 2 Day 8
1.5 mg Mean (SD) 0.53 (1.02) 0.54 (0.42) 0.67 (0.27) 0.97 (0.70) 0.56 (0.91) 0.63 (0.51)
Median 0.34 0.47 0.66 0.81 0.35 0.48
4.5 mg Mean (SD) 1.05 (0.44) 1.52 (0.66) 2.07 (0.84) 2.12 (0.96) 1.28 (0.70) 1.64 (0.75)
Median 0.92 1.29 1.80 2.53 1.10 1.38
Psychopharmacology (2011) 215:321–332 329sensitive to the impairing potential of esmirtazapine. Incre-
ments in SDLP were more pronounced than placebo after
single doses of esmirtazapine 1.5 and 4.5 mg in poor
metabolizers. After a week of repeated dosing, the low dose
of esmirtazapine no longer produced any relevant impair-
ment in poor metabolizers. However, while the absolute
effect on SDLP compared to placebo for poor metabolizers
was still below the non-inferiority margin of 2.5 cm, the
highest dose still produced an increment in SDLP after
1 week of dosing, which may indicate that tolerance to
impairing effects of esmirtazapine may not have been
complete after 7 days of dosing. These findings support the
notion that dose effects of esmirtapine on driving are
closely related to the drug's concentration in plasma.
For the extensive metabolizers, the results were similar to
those obtained in the main analysis. No relevant impairment
was observed after single and multiple doses of esmirtazapine
1.5 mg, whereas esmirtazapine 4.5 mg produced a small, but
clinically relevant increase in SDLP only after the initial dose.
A limitation of this explorative analysis on poor
metabolizers is (N=7) is that the present study was not
powered to demonstrate non-inferiority of esmirtazapine to
placebo in this small number of subjects (N=7). Small
numbers of subjects lead to wider confidence intervals
which increase the chance that upper limits of 95%
confidence intervals exceed a pre-specified limit, hamper-
ing their interpretation. For example, CIs in poor metabo-
lizers (N=7) are about twice as wide as those in extensive
metabolizers (N=25). Consequently, one must be cautious
when comparing the upper CI limit of the mean difference
in SDLP with placebo in poor metabolizers to a pre-
established alcohol equivalent, as the CI may actually
become less wide with increasing subject numbers. None-
theless, the results of the current analysis indicated more
pronounced driving impairment in poor metabolizers after
treatment with esmirtazapine. Although the exact magni-
tude of this driving impairment should be determined in a
larger subject sample when comparing to alcohol criterion
levels, these results are in line with the observation that
esmirtazapine has a dose-dependent effect on driving
performance, with impairment observed after a single dose
of 4.5 mg or higher. In subjects with higher exposure, such
as CYP2D6 poor metabolizers, the effect on driving
performance is therefore likely to be more pronounced
and impairment may be experienced even with a lower
dose. It should be noted that the CYP2D6 phenotype only
accounts for some of the inter-individual variability
observed in the driving performance. While an effect on
performance by gender and age, for example, was not
observed, other factors may still exist that significantly
influence the subject's susceptibility to drug effect on car
driving performance. Thus, the general implications of these
findings with regards to clinical practice may result in a
recommendation to start treatment with the lowest available
dose until therapeutic effect and tolerability are evaluated.
Esmirtazapine is being evaluated for the treatment of
insomnia in the dose range of 1.5–4.5 mg. Given the acute
effect of esmirtazapine at 4.5 mg on driving performance, a
1.5 mg/day starting dose of esmirtazapine treatment may be
recommended until therapeutic effect and tolerance is
evaluated and the need to increase the dose is confirmed.
It should be noted here that factors that influence
variability in drug response in general and, specifically, in
CYP2D6 phenotype do not just pertain to esmirtazapine.
For example, CYP2D6 is the major route of metabolism for
many sedative CNS drugs such as antidepressants, anti-
psychotics, opioids, and antihistamines (Ingelman-Sundberg
et al. 2007). Previous studies on the effects of drugs on
driving have never taken CYP2D6 genotype into account.
These explorative results indicate that subjects with genetic
CYP deviations (e.g., poor CYP 2D6 metabolizers) may be
at higher risk to be exposed to higher levels of drugs or
metabolites which have the potential to impair car driving. A
distinction in poor and extensive metabolizers may be of
particular importance when overall driving impairment levels
in the general study population are mild. Based on such an
overall finding, the conclusion would be that driving is not
contraindicated for a particular substance. However, factors
Adverse events Placebo Esmirtazapine Esmirtazapine Zopiclone
1.5 mg 4.5 mg 7.5 mg
(N=31) (N=30) (N=32) (N=30)
n (%) n (%) n (%) n (%)
Fatigue 6 (19.4) 10 (33.3) 9 (28.1) 2 (6.7)
Somnolence 1 (3.2) 4 (13.3) 8 (25.0) 0 (0.0)
Dysgeusia 3 (9.7) 2 (6.7) 1 (3.1) 1 (3.3)
Disturbance in attention 0 (0.0) 2 (6.7) 1 (3.1) 0 (0.0)
Headache 1 (3.2) 2 (6.7) 0 (0.0) 1 (3.3)
Poor quality sleep 5 (16.1) 1 (3.3) 0 (0.0) 1 (3.3)
Irritability 2 (6.5) 0 (0.0) 0 (0.0) 0 (0.0)
Table 4 Summary of adverse
events during the first 24 h after
first drug intake only with an
incidence of at least 5% in any
treatment group
330 Psychopharmacology (2011) 215:321–332which influence exposure to these drugs need to be taken
into account. Especially if there is a dose–response relation-
ship between car driving performance and dose of the drug,
then factors which increase exposure (e.g., gender, race, age,
orP450polymorphism)arelikelytodisplaymorepronounced
car driving impairment, which may reach levels of clinical
relevance.Consequently,itshouldberecommendedtoalways
take factors likely to affect drug exposure and response, such
as cytochrome P450 polymorphism into account when
designing future studies on drug effects on driving.
In the present study, single doses of zopiclone 7.5 mg
increased SDLP by 2.6 cm over placebo. Mean difference in
SDLP with placebo and its 95% CI upper limit exceeded the
non-inferiority margin of 2.5 cm and the CI excluded zero.
These data support findings from a number of previous studies
that assessed the influence of zopiclone 7.5 mg on SDLP as
measured in the standardized highway driving test (Leufkens et
al. 2009; Leufkens and Vermeeren 2009; Vermeeren 2004). All
of these studies demonstrated that evening doses of zopiclone
produced residual driving impairment in the morning. In all
studies, the impairing effects of zopiclone 7.5 mg were
comparable to a BAC between 0.5 and 0.8 mg/ml. In the
present study, impairment after zopiclone (verum) confirmed
the sensitivity of the highway driving test for sedative drug
effects and confirmed previous warnings concerning driving
(Leufkens et al. 2009; Leufkens and Vermeeren 2009;
Vermeeren 2004).
Overall, low doses of esmirtazapine (1.5 mg) did not
produce any relevant driving impairment after single and
repeated dosing. Driving impairment did occur after a higher
single dose of emirtazapine (4.5 mg) but resolved after
repeated doses. The explorative results on the subgroup of
poor metabolizers (N=7) indicated more pronounced car
driving impairment after both doses of esmirtazapine, but not
on the subgroup of extensive metabolizers (N=25). In these
individuals, impairment appeared to persist after 7 days after
administration of the highest dose.
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